Piper Sandler Maintains Buy Rating and $26 Price Target for Inventiva

Piper Sandler analyst Yasmeen Rahimi has reaffirmed a 'Buy' rating for Inventiva (IVA.US) and maintained a price target of $26. This decision reflects the firm's positive outlook on Inventiva's clinical-stage biopharmaceutical developments, indicating confidence in the company's valuation and market position.